Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic data and symptoms in PD patients involved in this study

From: Association between NMD3 and symptoms of Parkinson’s disease in Chinese patients

 NMD3 carriers (n = 178)NMD3 wildtypes (n = 39)p value
Age, mean (SD)57.03 (10.16)55.69 (10.24)0.461
Gender, female, N (%)73 (41.01)17 (43.59)0.907
Disease duration, mean (SD)4.79 (4.28)5.56 (3.89)0.275
Family history, N (%)17 (9.55)5 (12.82)0.550
Hoehn – Yahr staging, N (%)  0.869
 1.041 (23.03)10 (25.64) 
 1.529 (16.29)4 (10.26) 
 2.060 (33.71)14 (35.90) 
 2.532 (17.98)7 (17.95) 
 3.012 (6.74)4 (10.26) 
 4.04 (2.24)0 (0.00) 
 5.00 (0.00)0 (0.00) 
MDS-UPDRS, mean (SD)48.34 (27.10)43.05 (20.51)0.175
 Part I8.66 (6.16)7.51 (5.43)0.249
 Part II11.60 (7.71)10.08 (5.81)0.168
 Part III28.08 (17.45)25.46 (14.10)0.318
NMSS, mean (SD)36.23 (35.57)31.03 (27.42)0.315
SCOPA-AUT, mean (SD)10.92 (9.06)9.08 (8.56)0.233
PDQ-39, mean (SD)19.31 (17.84)16.23 (13.93)0.241
MMSE, mean (SD)26.31 (3.79)27.44 (2.89)0.042
MoCA, mean (SD)20.75 (6.68)23.15 (4.20)0.005
  1. MDS, movement disorders society; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NMSS, non-motor symptoms scale; SCOPA-AUT, scales for Outcomes in Parkinson’s disease – autonomic questionnaire; SD, standard deviation; PD, Parkinson’s disease; PDQ-39, 39-item Parkinson’s disease Questionnaire; UPDRS, unified Parkinson’s disease rating scale